ILT7/CD85g/LILRA4 Antibody (656688) [Alexa Fluor™ Plus 647]

• Reactivity: Hu
• Clone: 656688
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor Plus 647

ILT7/CD85g/LILRA4 Antibody (656688) [Alexa Fluor™ Plus 647] Summary

• Specificity: Detects human LILRA4/CD85g/ILT7 in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant human (rh) LILRA5, rhILT2, 3, 4, 5, or 6 is observed.
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Mouse

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for ILT7/CD85g/LILRA4 Antibody (656688) [Alexa Fluor™ Plus 647]

• CD85 antigen-like family member G
• CD85g antigen
• CD85g
• ILT7
• ILT-7
• ILT7MGC129598
• Immunoglobulin-like transcript 7
• leukocyte immunoglobulin-like receptor subfamily A member 4
• leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 4
• leukocyte immunoglobulin-like receptor, subfamily A (without TM domain), member4
• LILRA4
• MGC129597

Background

LILRA4, also known as ILT7 and CD85g, is a 499 amino acid (aa) type I transmembrane glycoprotein that contains four Ig-like domains in its extracellular region. LILRA4 is selectively expressed on plasmacytoid dendritic cells (pDC). It binds to BST2/CD317 on bone marrow stromal cells and associates with the gamma subunit of Fc epsilon RI. This receptor complex transmits signals that inhibit the TLR-induced production of type I interferon. The LILRA4-mediated interactions between pDC and tumor cells similarly inhibit the production of proinflammatory cytokines and contribute to reduced anti-tumor immune responses. Alternate splicing of human LILRA4 generates an isoform that lacks the N-terminal 43 aa of the extracellular domain.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.